| Primary information |
|---|
| sequence ID | Seq_5557 |
| Peptide sequence | NDGPPGRDGQPGHKGERGYPG |
| CancerPDF_ID | CancerPDF_ID10890, |
| PMID | 21805675 |
| Protein Name | Collagen alpha-2(I) chain |
| UniprotKB Entry Name | CO1A2_HUMAN |
| Fluid | Urine |
| M/Z | 2195.9632 |
| Profiling Technique | MALDI-TOF |
| Peptide Identification technique | MALDI-TOF-MS |
| Labelled/Label Free | Label Free |
| FDR | 1 |
| CancerPDF_ID | CancerPDF_ID10890, |
| p-Value | NA |
| Software | NA |
| Length | 21 |
| Cancer Type | Muscle-invasive bladder cancer |
| Database | SwissProt Database |
| Modification | "Oxidation: 4, 11, 20" |
| Number of Patients | 751 bladder cancer and 127 control |
| Regulation | Differentially expressed between cancer vs normal samples |
| Validation | Mann-Whitney tests and areas under receiver-operator characteristic |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| Peptide Atlas | NA |
| IEDB | NA |
| Primary information |
|---|
| sequence ID | Seq_5558 |
| Peptide sequence | NDGPpGRDGQpGHKGERGYpG |
| CancerPDF_ID | CancerPDF_ID3718, |
| PMID | 27026199 |
| Protein Name | Collagen alpha-2(I) chain |
| UniprotKB Entry Name | CO1A2_HUMAN |
| Fluid | Urine |
| fdr | 2194.97 |
| Profiling Technique | "CE-MS, Micro-TOF-MS" |
| Peptide Identification technique | MS-MS |
| Labelled/Label Free | Label Free |
| CancerPDF_ID | CancerPDF_ID3718, |
| p-Value | less than 0.05 |
| Software | Proteome Discoverer 1.2 |
| Length | 21 |
| Cancer Type | Bladder cancer |
| Database | Uniprot Human non-redundant Database |
| Modification | p:Hydroxy-Proline |
| Number of Patients | 425 for training(109 patients with Recurrent UBC cases and 316 negative for recurrence controls) and 211 for validation (55 UBC recurrent cases and 156 recurrent controls) |
| Regulation | Differentially expressed between recurrence of UBC vs recurrence control |
| Validation | Independent Validation |
| Sensitivity | For testing dataset 88% |
| Specificity | For testing dataset 51% |
| Accuracy | NA |
| Peptide Atlas | NA |
| IEDB | NA |